GENEXINE, INC.
28Patents
25Active
28Granted
48Portfolio score
Filing activity: Dec 6, 2000 → Nov 8, 2022 · 4 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7867491B2 | Immunoglobulin fusion proteins | Chemistry; Metallurgy | 19 | Active |
| US8883134B2 | Human interleukin-1 receptor antagonist—hybrid Fc fusion protein | Chemistry; Metallurgy | 17 | Active |
| US7910564B2 | Genes of IL-12P40 subunit mutated for improving the activity of IL-12 and use thereof for DNA vaccine adjuvant | Emerging Cross-Sectional Technologies | 7 | Active |
| US8586038B2 | Chimeric immunoglobulin fusion proteins | Chemistry; Metallurgy | 7 | Active |
| US10208099B2 | Modified interleukin-7 protein | Chemistry; Metallurgy | 5 | Active |
| US8137674B2 | Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer | Chemistry; Metallurgy | 5 | Active |
| US9000139B2 | Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer | Emerging Cross-Sectional Technologies | 3 | Active |
| US8529899B2 | Human growth hormone immunoglobulin fusion proteins | Chemistry; Metallurgy | 2 | Active |
| US9399665B2 | Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer | Emerging Cross-Sectional Technologies | 2 | Active |
| US10844104B2 | Modified interleukin-7 protein | Chemistry; Metallurgy | 2 | Active |
| US8586048B2 | G-CSF immunoglobulin fusion proteins | Chemistry; Metallurgy | 2 | Active |
| US11135262B2 | Methods of treating cervical cancer | Chemistry; Metallurgy | 2 | Active |
| US7253151B2 | Genes of IL-12P40 subunit mutated for improving the activity of IL-12 and use thereof for DNA vaccine adjuvant | Emerging Cross-Sectional Technologies | 1 | Expired |
| US11357827B2 | Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein | Human Necessities | 1 | Active |
| US11548927B2 | Formulation of modified interleukin-7 fusion protein | Chemistry; Metallurgy | 1 | Active |
| US10538569B2 | Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof | Chemistry; Metallurgy | 1 | Active |
| US11708399B2 | Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases | Chemistry; Metallurgy | 1 | Active |
| US11524054B2 | Method of treating anemia using long-acting EPO formulation | Chemistry; Metallurgy | 0 | Active |
| US8586531B2 | Erythropoietin immunoglobulin fusion proteins | Chemistry; Metallurgy | 0 | Active |
| US12427186B2 | Method for treating growth hormone deficiency employing hGH fusion protein | Physics | 0 | Active |
| US11883479B2 | Method for treating cervical cancer | Chemistry; Metallurgy | 0 | Active |
| US6818442B2 | AIDS DNA vaccine that prevents SIVmac239 virus infection in monkeys | Chemistry; Metallurgy | 0 | Expired |
| US7989425B2 | Vaccine enhancing the protective immunity to hepatitis c virus using plasmid DNA and recombinant adenovirus | Chemistry; Metallurgy | 0 | Expired |
| US12233113B2 | Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency | Human Necessities | 0 | Active |
| USRE46453E1 | Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer | General | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.